Evaluation of new anti-infective drugs for the treatment of infections of prosthetic hip joints. Infectious Diseases Society of America and the Food and Drug Administration
- PMID: 1477227
- DOI: 10.1093/clind/15.supplement_1.s177
Evaluation of new anti-infective drugs for the treatment of infections of prosthetic hip joints. Infectious Diseases Society of America and the Food and Drug Administration
Abstract
Infections of a prosthetic hip are of three types: acute contiguous, chronic contiguous, and hematogenous. Acute contiguous infections result from contamination of the operative field at the time of surgery; clinical manifestations of infection become apparent within 6 months. Chronic contiguous infections are diagnosed 6-24 months postoperatively and are believed to be caused by intraoperative contamination. Hematogenous seeding of prosthetic joints accounts for infections that develop > or = 2 years after surgery. Fever and pain or dysfunction of the joint may be the only signs or symptoms of prosthetic hip joint infection. Definitive diagnosis is established by culture of a needle aspirate from the joint space or by intraoperative culture. Prospective, randomized, double-blind or evaluator-blinded, active-control comparative studies are preferable to open trials. Success rates 10-14 weeks after completion of a 4- to 6-week course of antimicrobial therapy should be > or = 90%.
Similar articles
-
Evaluation of new anti-infective drugs for the treatment of acute hematogenous osteomyelitis in children. Infectious Diseases Society of America and the Food and Drug Administration.Clin Infect Dis. 1992 Nov;15 Suppl 1:S162-6. doi: 10.1093/clind/15.supplement_1.s162. Clin Infect Dis. 1992. PMID: 1477224
-
Evaluation of new anti-infective drugs for the treatment of infectious arthritis in adults. Infectious Diseases Society of America and the Food and Drug Administration.Clin Infect Dis. 1992 Nov;15 Suppl 1:S167-71. doi: 10.1093/clind/15.supplement_1.s167. Clin Infect Dis. 1992. PMID: 1477225
-
Evaluation of new anti-infective drugs for surgical prophylaxis. Infectious Diseases Society of America and the Food and Drug Administration.Clin Infect Dis. 1992 Nov;15 Suppl 1:S313-38. doi: 10.1093/clind/15.supplement_1.s313. Clin Infect Dis. 1992. PMID: 1477247
-
Infection in orthopaedic implants.J Hosp Infect. 1991 Jun;18 Suppl A:367-75. doi: 10.1016/0195-6701(91)90043-8. J Hosp Infect. 1991. PMID: 1679802 Review.
-
Balofloxacin Choongwae.Curr Opin Investig Drugs. 2003 Feb;4(2):224-9. Curr Opin Investig Drugs. 2003. PMID: 12669387 Review.
Cited by
-
[Diagnosis of chronic osteitis of the bones in the extremities. Relative value of F-18 FDG-PET].Unfallchirurg. 2007 Oct;110(10):859-66. doi: 10.1007/s00113-007-1302-y. Unfallchirurg. 2007. PMID: 17805505 German.
-
Population study evaluating fracture risk among patients with chronic osteomyelitis.PLoS One. 2017 Dec 21;12(12):e0189743. doi: 10.1371/journal.pone.0189743. eCollection 2017. PLoS One. 2017. PMID: 29267371 Free PMC article.
-
Ceramic composite with gentamicin decreases persistent infection and increases bone formation in a rat model of debrided osteomyelitis.J Bone Jt Infect. 2021 Jul 20;6(7):283-293. doi: 10.5194/jbji-6-283-2021. eCollection 2021. J Bone Jt Infect. 2021. PMID: 34345576 Free PMC article.
-
Efficacy of teicoplanin and autoradiographic diffusion pattern of [14C]teicoplanin in experimental Staphylococcus aureus infection of joint prostheses.Antimicrob Agents Chemother. 1998 Nov;42(11):2830-5. doi: 10.1128/AAC.42.11.2830. Antimicrob Agents Chemother. 1998. PMID: 9797211 Free PMC article.
-
Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection.Antimicrob Agents Chemother. 2002 Apr;46(4):1122-4. doi: 10.1128/AAC.46.4.1122-1124.2002. Antimicrob Agents Chemother. 2002. PMID: 11897604 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical